Version history

{
  "session_id": "sess_SDA-2026-04-08-gap-pubmed-20260406-062111-e3e328bf_task_9aae8fc5",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "scidex.core.llm.complete",
  "action": "propose",
  "content": "# Specific Therapeutic and Mechanistic Hypotheses for Uncommon Immune-Mediated Myelopathies\n\n## Background Context\nThe paper (PMID: 34715593) identifies gaps in understanding pathophysiology of uncommon myelopathies including MOG-antibody disease (MOGAD), antibody-negative autoimmune myelopathies, paraneoplastic syndromes, and GFAP astrocytopathy. The review notes that antibody discovery has clarified some cases but mechanisms of tissue injury remain incompletely characterized.\n\n---\n\n## Hypothesis 1: MOGAD Demyelination via FcγR-Mediated Macrophage Engagement\n\n**Title:** MOG-IgG induces spinal cord demyelination through Fcγ receptor-dependent macrophage activation independent of complement.\n\n**Mechanism:** MOG-IgG binds myelin oligodendrocyte glycoprotein on oligodendrocytes, engages activating Fcγ receptors (FcγRI, FcγRIII) on perivascular/spinal cord macrophages, triggering ADCP (antibody-dependent cellular phagocytosis) and release of pro-inflammatory cytokines (TNF-α, IL-1β). This mechanism may predominate over complement-dependent cytotoxicity, particularly in lesions with preserved axonal integrity.\n\n**Target Gene/Protein/Pathway:**\n- MOG (myelin oligodendrocyte glycoprotein) - antigen\n- FcγRI (FCGR1A), FcγRIII (FCGR3A) - activating receptors on macrophages\n- CSF1R signaling for macrophage survival/recruitment\n- IRAK4/MyD88 innate immune signaling downstream\n\n**Supporting Evidence:**\n- Takai et al. (2016, J Immunol) demonstrated MOG-IgG pathogenicity requires FcγR engagement in EAE models\n- Peschl et al. (2019, JNNP) showed MOGAD lesions have macrophage-predominant pathology with complement sparse\n- Spadaro et al. (2018, JCI) identified FcγR-dependent mechanisms in MOG-induced demyelination\n- McLaughlin et al. (2019, Ann Neurol) - MOGAD has distinct clinical/imaging features from AQP4-NMOSD\n\n**Predicted Experiment:** \n- Develop in vitro spinal cord slice cultures from transgenic human FcγR mice\n- Treat with MOG-IgG patient serum (or recombinant monoclonal antibodies) ± FcγR inhibitors (SYK inhibitor fostamatinib, FcγR-blocking antibodies)\n- Quantify myelin integrity (MBP immunostaining), oligodendrocyte death (OLIG2+ TUNEL+), macrophage activation (CD68+ area, iNOS expression)\n- Validate in passive transfer MOG-IgG mouse model with FcγR genetic deletion\n\n**Confidence:** 0.72\n\n---\n\n## Hypothesis 2: Paraneoplastic Myelopathy - Viral Antigen Mimicry and CD8+ T Cell-Mediated Neuronal Injury\n\n**Title:** Paraneoplastic myelopathies involve CD8+ T cell recognition of viral/cancer antigens presented by spinal motor neurons via MHC class I, causing necroptotic neuronal death.\n\n**Mechanism:** Cross-reactive T cell receptors recognize both viral (EBV, HSV, HHV-6) or cancer antigens and neuronal peptides presented on MHC class I (HLA-A*02:01, B*07:02). Perforin/granzyme B release from clonally expanded CD8+ T cells induces caspase-8-mediated apoptosis or RIPK3-dependent necroptosis in spinal motor neurons, explaining the irreversible disability despite immunosuppression.\n\n**Target Gene/Protein/Pathway:**\n- HLA-A, HLA-B (MHC class I molecules) - antigen presentation\n- CD8A/CD8B T cell receptor engagement\n- Perforin (PRF1), Granzyme B (GZMB) - cytotoxic granules\n- RIPK3/MLKL - necroptosis pathway in neurons\n- TCR clonality metrics (TCRβ sequencing)\n\n**Supporting Evidence:**\n- Pittock & Lennon (2008, Arch Neurol) on Yo antibody paraneoplastic cerebellar degeneration mechanisms\n- Roberts et",
  "tokens_used": "860",
  "persona_id": "persona-theorist"
}